INSILICO (03696.HK): Servier AI drug discovery milestone hit
- The collaboration, first announced in early 2026, is worth up to USD 888 million, including USD 32 million in upfront and near-term research milestone payments.
- Both oncology programmes, run on the company's proprietary Pharma.AI platform, have completed target nomination.
NewTimeSpace News: On 20 October 2026, InSilico Medicine Cayman TopCo (stock code: 03696) announced that its multi-year artificial intelligence-driven drug discovery collaboration with Servier, an independent international pharmaceutical group governed by a foundation, has reached an early drug discovery milestone, with the first programme triggering an undisclosed milestone payment to the company after meeting preset criteria.
The collaboration, first announced in early 2026, has a total value of up to USD 888 million, including USD 32 million in upfront and near-term research milestone payments. Both oncology programmes, run on the company's proprietary end-to-end Pharma.AI platform, have completed target nomination. The company cautioned that it cannot guarantee any forward-looking statements will be achieved and that the financial and other data disclosed have not been audited or reviewed by its auditors.
- INSILICO (03696.HK): Nominates ISM9546 as 35th Preclinical Candidate
- INSILICO (03696.HK): Nominates GIPR antagonist ISM1354 as PCC
- INSILICO (03696.HK): Signs AI co-development deal worth up to tens of millions of USD
- INSILICO (03696.HK): Chairman increases shareholding by 113,500 shares, votable interest rises to approximately 8.02%
- INSILICO (03696.HK): AI-Driven Candidate Rentosertib Completes First Patient Dosing in Phase III IPF Trial
